[Treatment of Meige disease with a XXXX receptor agonist].

@entity1 @entity3520 @entity1246 @entity935 @entity1282 @entity9663 @entity3519 @entity1772 @entity33057
The spontaneous occurrnce of @entity9663 and @entity3520 movements in face muscles, particularly those of the perioral and mandibular regions, has been named @entity33057 . Other @entity3520 as spasmodic torticollis, @entity1282 , @entity3519 of the limbs may, eventually, be present in the same @entity1 . There is very little knowledge about the pathology of this disease. Many hypotheses concerning the pathophysiology of this entity have been put forward, most of them correlating the clinical response to several drugs with known action on the neurotransmitter system of the brain. There are some evidences that it may exist a dopaminergic preponderance in the disease. In the nigro-striatal pathway, one of the retrograde loops in the feed-back control of @entity935 synthesis by nigral neurons is dependent on @entity1246 . Increasing @entity1246 activity through @entity1246 agonists that cross the blood-brain barrier could result in a decreased dopaminergic action in the nigro-striatal pathway and, thus, ameliorate the @entity3520 which might have been produced by its increased function. We have used @entity1772 , a @entity1246 -agonist drug, to treat five @entity1 with @entity33057 , in a single-blinded trial. These were four females and one male, with age ranging from 50 to 63 years. The drug was started at 20mg/day, being increased by 10mg each three days reaching a maximum dose of 70mg/day. One of the @entity1 showed marked improvement of @entity9663 and @entity3519 and a second @entity1 had a moderate improvement in the same symptoms. Another @entity1 showed moderate @entity3519 , but had no benefit in the facial movements.(ABSTRACT TRUNCATED AT 250 WORDS)
